Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European heart …, 2021 - academic.oup.com
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European Heart …, 2021 - search.ebscohost.com
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon, G Vilahur… - European heart …, 2021 - ddd.uab.cat
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

[PDF][PDF] Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European Heart …, 2021 - academic.oup.com
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European heart …, 2021 - pubmed.ncbi.nlm.nih.gov
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European Heart …, 2021 - eprints.whiterose.ac.uk
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

[PDF][PDF] Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European Heart …, 2021 - pdfs.semanticscholar.org
Despite advances in therapy, a diagnosis of diabetes mellitus (DM) is associated with
increased morbidity and reduced lifespan, mainly due to vascular complications. 1–3 …

Antithrombotic therapy in diabetes: Which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European Heart …, 2021 - researchprofiles.herts.ac.uk
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - EUROPEAN HEART …, 2021 - publicatt.unicatt.it
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Antithrombotic therapy in diabetes: Which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon, D Gorog… - European Heart …, 2021 - uhra.herts.ac.uk
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …